Zobrazeno 1 - 10
of 145
pro vyhledávání: '"J Sisler"'
Autor:
Daniel J. Sisler, Trista K. Hinz, Anh T. Le, Emily K. Kleczko, Raphael A. Nemenoff, Lynn E. Heasley
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe KRAS(G12C) mutation is the most common genetic mutation in North American lung adenocarcinoma patients. Recently, direct inhibitors of the KRASG12C protein have been developed and demonstrate clinical response rates of 37-43%. Importa
Externí odkaz:
https://doaj.org/article/cb227c2f9f5440f7a6ba0d3df80f32ec
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
L. A. Shafer, J. R. Walker, C. Waldman, V. Michaud, C. Yang, C. N. Bernstein, L. Hathout, J. Park, J. Sisler, K. Wittmeier, G. Restall, H. Singh
Publikováno v:
Endoscopy International Open, Vol 06, Iss 06, Pp E706-E713 (2018)
Introduction Many endoscopists do not use split-dose bowel preparation (SDBP) for morning colonoscopies. Despite SDBP being recommended practice, they believe patients will not agree to take early morning bowel preparation (BP). We assessed patients
Externí odkaz:
https://doaj.org/article/e221da864bc9463ebd89c039908b72f0
Autor:
Daniel J Sisler, Trista K Hinz, Anh T Le, Emily K Kleczko, Raphael A Nemenoff, Lynn E Heasley
The KRAS(G12C) mutation is the most common genetic mutation in North American lung adenocarcinoma patients. Recently, direct inhibitors of the KRASG12C protein have been developed and demonstrate clinical response rates of 37-43%. Importantly, these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bde11dd6433898d1c6439b0f1b7e3c60
https://doi.org/10.1101/2022.08.19.504555
https://doi.org/10.1101/2022.08.19.504555
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lynn E. Heasley, Daniel J Sisler
Publikováno v:
Future Medicinal Chemistry. 11:1083-1086
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::790c0f6d129d514f270c294aeed61d25
https://doi.org/10.4155/fmc-2018-0292
https://doi.org/10.4155/fmc-2018-0292
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Trista K. Hinz, Colin Sempeck, Lindsay Marek, Bonnie L. Bullock, Howard Li, Daniel J Sisler, Natalia Gurule, Molishree Joshi, Raphael A. Nemenoff, Sean Korpela, Lynn E. Heasley
Publikováno v:
Molecular Cancer Research. 18:B51-B51
Mutations in the KRAS oncogene are frequent in lung adenocarcinomas (LUADs). Unfortunately, KRAS lacks a pharmacologically available inhibitor for precision oncology. Immunotherapies have recently become available and are now FDA approved for LUAD, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8fdbac9e1593b206ef827e63eae3e253
https://doi.org/10.1158/1557-3125.ras18-b51
https://doi.org/10.1158/1557-3125.ras18-b51
Autor:
L Shafer, C Waldman, J R Walker, V Michaud, C N Bernstein, L Hathout, J Park, J Sisler, G Restall, K Wittmeier, H Singh
BACKGROUND: European and North American guidelines strongly recommend use of split-dose bowel preparation (SDBP) for all colonoscopies based on evidence from meta-analyses. Interviews and focus groups with endoscopists indicate some reluctance to use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee6b44328c04b8a495b985553839ab6
https://europepmc.org/articles/PMC6507758/
https://europepmc.org/articles/PMC6507758/
Autor:
Janine Giese-Davis, J. Chobanuk, Barbara Walley, A. Taylor, Linda E. Carlson, Y. Brandelli, Anil A. Joy, Desiree Hao, L. Zhong, L. Shirt, J.L. McCormick, J. Sisler, Cindy Railton, Harold Lau
Publikováno v:
Current Oncology
Volume 25
Issue 1
Pages 3766-72
Volume 25
Issue 1
Pages 3766-72
No standardized measures specifically assess cancer survivors&rsquo
and healthcare providers&rsquo
experience of Survivor Care Plans (scps). We sought to develop two care plan evaluation (cpe) measures, one for survivors (cpe-s) and one for
and healthcare providers&rsquo
experience of Survivor Care Plans (scps). We sought to develop two care plan evaluation (cpe) measures, one for survivors (cpe-s) and one for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9b51df2290b3a5a5cf977584f16a77d
https://europepmc.org/articles/PMC5832293/
https://europepmc.org/articles/PMC5832293/